Researchers compare the impact of medication alone or deep brain stimulation of the subthalamic nuclei in quality of life in Parkinson’s patients.
Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC
Non-small lung cancer (NSCLC) that progressed on immunotherapy did not benefit from the combination of a PD-L1 inhibitor and a targeted agent versus chemotherapy, a
June 21, 2024